Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Cadila Healthcare Limited
  6. News
  7. Summary
    CADILAHC   INE010B01027

CADILA HEALTHCARE LIMITED

(CADILAHC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cadila Healthcare : Zydus announces ‘first patient' randomised in EVIDENCES-X TM Phase II(b) clinical trial of Saroglitazar Mg in NASH

10/22/2021 | 09:14am EST

www.zyduscadila.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation is complete.

Reference ID IP Address Date and Time
8946b0739bb182bd1a59ff3123401467 18.188.216.125 10/22/2021 01:03 PM UTC

Disclaimer

Cadila Healthcare Limited published this content on 22 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2021 13:13:01 UTC.


ę Publicnow 2021
All news about CADILA HEALTHCARE LIMITED
11/24Cadila Healthcare Ltd. Enter into A Manufacturing License and Technology Transfer Agree..
CI
11/23CADILA HEALTHCARE : Zydus develops new treatment for patients suffering from Chronic Kidne..
PU
11/22Cadila Healthcare Seeks Regulatory Approval for New Kidney Disease Drug Desidustat
MT
11/22Zydus Cadila Submits the New Drug Application to the Drug Controller General of India f..
CI
11/21Cadila Healthcare Gets US FDA Nod to Market Cancer Treatment Drug
MT
11/20Zydus Cadila Receives Final Approval from USFDA for Decitabine Injection
CI
11/18Indian Indices End in Red on Thursday; Tata Motors Slumps 4%
MT
11/18CADILA HEALTHCARE : Zydus Cadila gets 180-day exclusivity for Nelarabine injection, announ..
PU
11/17Cadila Healthcare Gets US FDA's Nod to Sell Nelarabine Injection in US
MT
11/17Zydus Cadila Gets 180-Day Exclusivity for Nelarabine Injection, Announces Final Approva..
CI
More news
Financials
Sales 2022 157 B 2 102 M 2 102 M
Net income 2022 32 988 M 441 M 441 M
Net Debt 2022 21 408 M 286 M 286 M
P/E ratio 2022 18,0x
Yield 2022 0,98%
Capitalization 476 B 6 340 M 6 366 M
EV / Sales 2022 3,16x
EV / Sales 2023 2,85x
Nbr of Employees 24 412
Free-Float 25,1%
Chart CADILA HEALTHCARE LIMITED
Duration : Period :
Cadila Healthcare Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CADILA HEALTHCARE LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 465,25 INR
Average target price 566,07 INR
Spread / Average Target 21,7%
EPS Revisions
Managers and Directors
Sharvil Pankajbhai Patel Managing Director & Executive Director
Nitin Dalsukhrai Parekh Chief Financial Officer
Pankaj Ramanbhai Patel Non-Executive Chairman
Ganesh Narayan Nayak Chief Operating Officer & Executive Director
Dhaval N. Soni Secretary & Compliance Officer